Fiche centre
University of Alabama Birmingham
Birmingham — United States
Essais liés9clinical trials
VilleBirminghamlocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT04619420
Essais cliniques associés
9| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Capecitabine | Cancer | Phase 2 | NCT05693766 | INSIGHT — Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort | RECRUITING |
| JNJ-63733657 | Alzheimer | Phase 2 | NCT04619420 | Autonomy — A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease | TERMINATED |
| Lab Assay for seven genetic variants for Parkinson's Disease | Parkinson | À vérifier | NCT04994015 | Parkinson's Foundation PD GENEration Genetic Registry | RECRUITING |
| Tazbentetol | Sclérose latérale amyotrophique | À vérifier | NCT07088159 | Intermediate-size Patient Population Expanded Access Protocol | AVAILABLE |
| ASSESS ALL ALS Study | Sclérose latérale amyotrophique | À vérifier | NCT06578195 | ASSESS ALL ALS Study | RECRUITING |
| ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) | Sclérose latérale amyotrophique | À vérifier | NCT04363684 | ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) | RECRUITING |
| PREVENT ALL ALS Study | Sclérose latérale amyotrophique | À vérifier | NCT06581861 | PREVENT ALL ALS Study | RECRUITING |
| APL-130277 | Parkinson | Phase 3 | NCT02542696 | Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease | COMPLETED |
| Fenebrutinib | SEP | Phase 3 | NCT04586010 | FENhance — A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING |